Three Hospital Systems in England Launch Clinical Trial of AI Technology to Detect and Grade Prostate Cancer
The University of Oxford, in collaboration with Paige, a pioneer in clinical AI applications for cancer diagnosis, has launched a live clinical trial of AI technology designed to detect and grade prostate cancer. The study, known as ARTICULATE PRO, involves three hospital systems across England: North Bristol Trust Southmead Hospital, University Hospitals Coventry and Warwickshire, and Oxford University NHS Foundation Trust.
The Study’s Goal
The central focus of ARTICULATE PRO is patients, with the goal of safely and effectively ensuring they benefit from powerful AI technology. The study aims to evaluate the potential of AI to improve patient outcomes against a backdrop of rising prostate cancer cases.
The Prostate Suite
The Prostate Suite, the AI system being trialled, is designed to assist pathologists in detecting, grading, and measuring tumours in prostate biopsies and tissue samples. Pathologists at the three hospitals are assessing how this AI technology impacts their clinical decision-making, pathology service delivery, and resource utilisation in real-world settings.
Benefits of the AI Technology
The study’s lead, Professor Clare Verrill, said that the AI technology has the potential to increase efficiency and improve reproducibility of results for patients. Dr. Jon Oxley, Uropathologist and Bristol lead of ARTICULATE PRO, added that the technology has achieved a level of validation and performance that allows safe and effective live clinical use.
The Study’s Significance
The study is notable for its implementation across hospitals using different digital pathology scanners and information systems, serving distinct patient populations. This diversity allows for a comprehensive assessment of how Paige’s AI technology can best serve patients, histopathologists, and hospital systems in prostate cancer diagnosis.
Conclusion
The ARTICULATE PRO study has the potential to revolutionize prostate cancer diagnosis by integrating AI technology into clinical practice. The results of this trial could pave the way for wider adoption of AI in cancer diagnosis across the UK and beyond.
FAQs
Q: What is the goal of the ARTICULATE PRO study?
A: The goal is to evaluate the potential of AI to improve patient outcomes in prostate cancer diagnosis.
Q: What is the Prostate Suite?
A: The Prostate Suite is an AI system designed to assist pathologists in detecting, grading, and measuring tumours in prostate biopsies and tissue samples.
Q: What are the benefits of the AI technology?
A: The AI technology has the potential to increase efficiency and improve reproducibility of results for patients.
Q: How is the study being implemented?
A: The study is being implemented across three hospital systems using different digital pathology scanners and information systems, serving distinct patient populations.
